Longitudinal recurrence risk of adjuvant cytotoxic chemotherapy and gefitnib in resected lung cancer: A combined analysis of phase III studies
Hiroaki Akamatsu(Army Medical University), Tetsuya Mitsudomi(Kindai University), Tadashi Aoki(Niigata Cancer Center Hospital), Hirotsugu Kenmotsu(Shizuoka Cancer Center), Toshihiro Misumi(Yokohama City University), Tomomi Nishikawa(National Cancer Center Hospital East), Masahiro Tsuboi(National Cancer Center Hospital East), Yuriko Takeda(Yokohama City University), Hirohito Tada(Osaka City General Hospital), Haruko Daga(Osaka City General Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Nobuyuki Yamamoto(National Cancer Center Hospital East), Noriaki Sakakura(Aichi Cancer Center), Kyoichi Okishio(NHO Kinki Chuo Chest Medical Center), Motohiro Yamashita(Shikoku Cancer Center), Hiroyasu Shoda(Hiroshima City Asa Citizens Hospital)
Cited by 2
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k